Pargluva Fluid Retention, Cardiac Risk To Be Central Issues At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Data showing heart failure rates with 5 mg dose of muraglitazar may be higher than with 30 mg pioglitazone (Lilly/Takeda's Actos) in type 2 diabetes patients will be presented to committee at Sept. 9 review.
You may also be interested in...
Bristol/Merck Receive Pargluva "Approvable" Letter
FDA cites need for additional information on the cardiovascular safety profile for the dual PPAR diabetes therapy.
Bristol/Merck Receive Pargluva "Approvable" Letter
FDA cites need for additional information on the cardiovascular safety profile for the dual PPAR diabetes therapy.
Bristol/Merck's Pargluva Combination Use With Sulfonylureas Not Recommended
Committee supports use of the type 2 diabetes therapy muraglitazar as monotherapy and in combination with metformin, but says safety with sulfonylureas has not been adequately studied.